Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells by Scheck, Adrienne C et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Complementary and 
Alternative Medicine
Open Access Research article
Anticancer activity of extracts derived from the mature roots of 
Scutellaria baicalensis on human malignant brain tumor cells
Adrienne C Scheck1,2, Krya Perry1,3, Nicole C Hank1 and W Dennis Clark*3
Address: 1Neuro-Oncology Research, Barrow Neurological Institute® of St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA, 
2Neurosurgery Research, Barrow Neurological Institute® of St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA and 3School of Life 
Sciences, Arizona State University, Tempe, AZ 85287-4501, USA
Email: Adrienne C Scheck - adrienne.scheck@chw.edu; Krya Perry - Krya.Perry@sccmail.maricopa.edu; Nicole C Hank - nicole.hank@chw.edu; 
W Dennis Clark* - wdclark@usbotanicals.net
* Corresponding author    
Abstract
Background: Flavonoid-rich extracts from the mature roots of Scutellaria baicalensis have been
shown to exhibit antiproliferative effects on various cancer cell lines. We assessed the ability of an
ethanolic extract of S. baicalensis root to inhibit the proliferation of malignant glioma cells.
Methods: Cell lines derived from primary and recurrent brain tumors from the same patient and
cells selected for resistance to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea
(BCNU) were used to identify antiproliferative effects of this extract when used alone and in
conjunction with BCNU.
Results and discussion: Results indicated that Scutellaria baicalensis not only inhibits cellular
growth in recurrent and drug resistant brain tumor cell lines, but also demonstrates an increased
inhibitory effect when used in conjunction with BCNU.
Conclusion: The results of this study support the efficacy of S. baicalensis as an anticancer agent
for glioblastomas multiforme and a potential adjuvant treatment to current chemotherapeutic
agents used in the treatment of both primary and recurrent GBMs. Further studies of the effects
of individual flavonoids alone and in combination with each other and with currently used therapies
are needed.
Background
Malignant gliomas are one of the more lethal forms of
cancer. An estimated 18,000 new cases of brain and cen-
tral nervous system tumors are diagnosed each year and
approximately 13,000 people die of their disease in the
United States alone [1]. Those diagnosed with the most
malignant form of astrocytoma (glioblastoma multi-
forme, GBM) have a dismal prognosis. The median sur-
vival rate of one year has remained essentially unchanged
for a number of years despite aggressive treatment regi-
mens that include surgery, radiation and chemotherapy.
Complete surgical removal of the tumor is typically not
achieved due to the infiltrative nature of these tumors and
while radiation and chemotherapy kill the majority of the
remaining tumor cells, the rapid recurrence of these
tumors suggest the presence within the primary tumor of
a subpopulation of cells intrinsically resistant to therapy
and capable of survival and growth within the tumor bed
following therapy [2,3]. When these tumors recur, they
are typically refractory to additional courses of the same
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therapies. Improvement in the survival and quality of life
of glioma patients requires the design of new therapies or
therapeutic combinations that are effective and preferably
have fewer side effects than those presently available.
One promising new source of therapeutic agents has been
discovered in plant secondary metabolites, irregularly
occurring compounds that characterize certain plants or
plant groups [4]. Recent interest in these secondary
metabolites has been focused upon their medicinal prop-
erties [5]. For example, flavonoids are a large group of aro-
matic plant secondary metabolites that are produced in
the plant for the purpose of protection from photosyn-
thetic stress, reactive oxygen species (ROS), wounds and
herbivores. Studies of flavonoids have produced the most
compelling data for the antitumor activities of plant sec-
ondary metabolites in various types of cancers [6], and
several flavonoids have been shown to inhibit cancer
development while exhibiting antioxidant activities in
various animal models [7-11]. Furthermore, some studies
suggest that the most promising use of these compounds
may be as an adjuvant to currently used therapies [12,13].
Numerous cancer research studies have been conducted
using traditional medicinal plants in an effort to discover
new therapeutic agents that lack the toxic side effects asso-
ciated with current chemotherapeutic agents. One of the
more versatile plants used as a source of flavonoids is the
root of the traditional Chinese medicinal herb Baikal
skullcap (Scutellaria baicalensis), a member of the mint
family [14]. Traditionally, the dried roots of S. baicalensis
were extracted and used in a Chinese herbal medicine
"Huang Qin" to treat a variety of ailments [15], and Scutel-
laria baicalensis has remained an important herb in both
Chinese and Japanese traditional prescriptions, such as
"Xiao-Chai-Hu-Tang" which is used in the treatment of
viral hepatitis and a variety of tumors [16-18]. Various fla-
vonoids isolated from this traditional Chinese medicinal
plant were shown to have antiandrogenic and growth
inhibitory activity against prostate cancer cells in vitro and
in vivo [19-26]. In addition, extracts and isolated flavo-
noids from this herb have been shown to relieve oxidative
stress and immune dysfunction associated with the onset
and progress of cancer [8]. Studies have also demon-
strated that flavonoids from S. baicalensis have the ability
to arrest the cell cycle of tumor cell lines that are resistant
to multiple chemotherapeutic drugs [27] and act as inhib-
itors of key steps necessary for the progression of tumor
angiogenesis [28].
More recently, Scutellaria baicalensis was used as a compo-
nent of PCSPES, an herbal mixture that showed efficacy in
laboratory trials for prostate cancer, small-cell lung cancer
and acute myeloid leukemia [29-34]. Despite these prom-
ising results in human trials, this herbal mixture was
removed from the market due to concerns about contam-
ination [35]. Subsequent work has shown that flavonoids
from S. baicalensis were likely to have been at least one of
the active ingredients in this herbal mixture [31], and S.
baicalensis extract and its constituents have been shown to
cause reduced expression of the androgen receptor and
androgen regulated genes in prostate carcinoma [20].
Recent studies have also shown that the flavonoid-rich
extract from the roots of S. baicalensis exhibit antiprolifer-
ative effects upon prostate, squamous, colon, breast, lung,
and liver carcinomas, as well as various leukemia cell lines
[16,21,36,37]; however, there have been no studies con-
ducted in brain tumors despite suggestions that compo-
nents of this extract can have effects on microglia in the
brain [38]. We, therefore, tested an extract from the root
of S. baicalensis to determine if it had antiproliferative
effects on cells from human malignant brain tumors
alone or in combination with 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU, carmustine), an alkylating agent
commonly used in the treatment of human brain tumors.
Methods
Plant material extraction
Secondary metabolites, including flavonoids and other
phenolic compounds, were extracted from ground mature
roots of S. baicalensis (common name Huang Qin) using
95% ethanol. Commercially available roots from a Cali-
fornia importer of Chinese herbal medicines (Win Hop
Fung, Los Angeles) were obtained and ground into a fine
powder using a Scientific Apparatus™ soil mill. The root
powder was stirred for 24 hours in a 95% ethanol solution
in order to extract the secondary metabolites and flavo-
noids. The crude extract was filtered through a PTFE mem-
brane filter using a Swinney (Millipore Corp., Bedford,
MA) filtering device. The extract was dried and quantified
for the total amount of crude extract. A stock solution was
prepared at 25 mg of solid per ml in absolute ethanol and
was further diluted with sterile water immediately before
treatment of the cells to achieve a concentration of 10 mg/
ml in a 40% (v/v) ethanol solution.
Cell culture
Cell lines grown from primary and recurrent GBMs from
three patients (Table 1) were cultured using previously
established protocols [39]. Primary tumors are designated
with a 2-letter code (ME, DI) or the last 2 digits of the year
followed by a 2-letter code (00WA). The recurrent tumors
from the same patient receive the same code with the
addition of an "R" (ME/MER, DI/DIR). Following surgery
for their primary tumor, both patients from whom we
received recurrent tumor samples received 1,3-bis(2-chlo-
roethyl)-1-nitrosourea (BCNU, carmustine) and radiation
therapy. Despite therapy, both tumors recurred and the
patients underwent additional surgery. Tumor cell line
00WA (Table 1) was selected for use in this study as a low-BMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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passage cell line derived from a primary tumor and serial
passaged 5 times. Normal glial cells (HJ) grown from a
sample obtained from a crainiotomy done for treatment
of trauma were also cultured following previously estab-
lished protocols [39]. All cell lines were cultured in Way-
mouth's MAB 87/3 (Mediatech, Herndon, Virginia)
containing 20% Fetal Bovine Serum (FBS; Intergen Co.,
Purchase, NY) and incubated at 37°C in a humidified
atmosphere of 5% CO2. To select for the subpopulation of
cells resistant to 10 μg/ml BCNU, cells were treated with
gradually increasing concentrations of drug as described
[40,41]. Cells were washed with MAB without serum; they
were then mock-treated using MAB alone or treated with
increasing concentrations of BCNU in MAB (2.5, 5.0, 7.5,
10 μg/ml) for 1 hour at 37°C with 5% CO2. Cells were
subsequently washed and fed with MAB containing 20%
FBS. The cells were treated for three consecutive days then
allowed to grow. Treatment was repeated several times
until the cells in culture were resistant to 10 μg/ml of
BCNU (ME Drug/MER Drug and DI Drug/DIR Drug) as
evidenced by the absence of cell death compared to that
observed in the mock-treated cultures. Cells were re-
treated with 10 μg/ml BCNU every 8–10 passages to
maintain the resistant phenotype.
AlamarBlue™ metabolic assay
Cells were seeded at a density of approximately 1 – 4 × 103
cells in 200 μl per well. Following a 24-hour incubation
period, cells were treated with 100 μg/ml of S. baicalensis
extract containing 0.4% ethanol (v/v) in 200 μl of
medium. Mock treatment consisted of a 0.4% (v/v) solu-
tion of ethanol in 200 μl of medium. Cellular metabolic
activity was assayed using AlamarBlue™ (Serotec, Raleigh,
NC) and the manufacturer's protocol at 0, 1, 3, 7, 10, and
15 days following treatment. The fluorescent reading was
performed using a microtiter plate reader (485 nm λ exci-
tation, 595 λ nm emission).
Colony forming assay
A Colony Forming Assay (CFA) was used to verify that the
cells remaining metabolically active following treatment
with S. baicalensis extract were also capable of prolifera-
tion. Cells were diluted and divided into aliquots contain-
ing approximately 1.5 × 103 cells. Aliquots were treated
with a single dose of 0 (untreated), 10, 25, 50, 75, 100,
150 and 200 μg/ml of the extract in MAB 87/3 medium
supplemented with 20% FBS for 1 hour. Following incu-
bation, cells were washed three times with fresh medium.
Cells were resuspended in the medium and aliquots of 1.5
ml containing approximately 2 × 103 cells were dispensed
into three 60 mm culture dishes. Cells were cultured for at
least 6 divisions, approximately 14 days, before they were
fixed with methanol and stained with 4% Giemsa stain.
Colonies, defined as 50 or more cells, were counted and
plotted as a percentage of the control (untreated) colo-
nies.
Trypan blue exclusion cell viability assay
The cells were plated at approximately 1 × 105 cells per
well in 6-well tissue culture plates in 2 ml of medium and
incubated at 37°C at 5% CO2. After 24 hours, the
medium was removed and replaced with fresh medium
plus 20% FBS and supplemented with S. baicalensis extract
(0, 25, 50, 100, 150, and 200 μg/ml) or a combination of
S. baicalensis extract and BCNU (2.5 or 5 μg/ml). Cells
were harvested 48 hours after treatment by digestion with
0.25% trypsin-EDTA solution at 37°C for 2–3 minutes.
The cells were stained with trypan blue and live cells were
enumerated. Cell counts were expressed as mean ± stand-
ard deviation (SD).
Statistical analysis
All results are expressed as mean ± standard deviation
(SD). Statistical differences between correlated samples
were evaluated using Student's t-test and noted to be sig-
nificantly different where p < 0.05. Student t-test calcula-
tions were assessed on the VassarStats Statistical
Computation website [42]. Composite treatments were
compared using one-way analysis of variances (ANOVA)
and considered significantly different where probability
values were found to be equal to or less than 0.05. All
ANOVA tests, as well as mean and SD calculations, were
performed using GraphPad Prism (GraphPad Software,
Inc., San Diego, USA).
Table 1: Patient information
Tumor codea Ageb Sex Diagnosisc Treatmentd Days between primary and secondary surgery Survival (days)
DI/DIR 38 F GBM Irradiation and BCNU 111 426
ME/MER 49 F GBM Irradiation and BCNU 138 285
00WA 39 M GBM NAe NA NAvf
a The tumor code is a random 2 letter code. Recurrent tumor from the same patient receives the same code with the addition of R. For each 
patient the primary and recurrent tumors were diagnosed by the same neuropathologist.
b Age in years at diagnosis of primary tumor.
c GBM = glioblastoma multiforme.
d BCNU = 1,3-bis(2-chloroethyl)-1-nitrosourea.
e NA = not applicable since this was a primary tumor.
f NAv = not availableBMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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Results
Effects of S. baicalensis on glioma cell metabolic activity
The metabolic inhibitory effects of an extract from S. bai-
calensis were studied in cell lines cultured from paired pri-
mary (ME) and recurrent (MER) glioblastoma multiforme
(GBM) tumors obtained from a single patient, as well as
primary and recurrent cells that have been selected in vitro
for resistance to 10 μg/ml of BCNU (ME Drug/MER
Drug). Metabolic activity was assessed at 0, 1, 3, 7, 10, and
15 days following treatment with 100 μg/ml of the extract
using an AlamarBlue metabolic assay. All wells were sub-
confluent when the experiment was begun to allow for
changes in cell growth. In this way, we would see a differ-
ence regardless of whether the effect of the extract was
cytotoxic or cytostatic. There was a significant (p < .05; n
= 5) difference in the metabolic activity exhibited by cells
treated with S. baicalensis extract compared with mock- or
ethanol treated cells. There was no increase in metabolic
activity exhibited in the ME and MER glioma cell lines, as
well as subpopulations of these cell lines that were
selected for BCNU resistance (ME Drug and MER Drug)
for the 15 day duration of the experiment (Figure 1),
while the untreated glioma cells (controls) exhibited
exponential increases in metabolic activity. As an addi-
tional control, glioma cells were treated with a 0.4% (v/v)
ethanol solution (solvent vehicle). Although there was
some difference in fluorescence between untreated and
ethanol treated MER cells at day 7 (Figure 1D) and 10
(Figure 1C), there was good growth in all four cell lines
and the ethanol-treated cells showed no significant
decrease in metabolic activity compared to the untreated
control cells by the fifteenth day of culture. Microscopic
Time course treatment of ME series cells with S. baicalensis extract Figure 1
Time course treatment of ME series cells with S. baicalensis extract. Metabolic activity was measured using AlamarBlue™. 
Wells were subconfluent on Day 0. Cells were left untreated (■-■), mock treated with 0.4% ethanol (∇-∇) or treated with a 
0.4% ethanol solution containing 100 μg/ml S. baicalensis extract (-). Data is mean ± SD using 5 replicates. (A) cells from 
primary tumor (ME), (B) ME cells selected for resistance to 10 μg/ml BCNU (ME drug), (C) cells from recurrent tumor (MER), 
(D) cells from recurrent tumor selected for resistance to 10 μg/ml BCNU (MER drug).BMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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examination showed extensive cytopathic effect (CPE) in
cells treated with the S. baicalensis extract (data not
shown).
Effects of S. baicalensis on glioma cell viability and 
proliferation
Colony forming assays were done to demonstrate a dose
response to the S. baicalensis extract and to show that the
effect is cytopathic and not cytostatic. Cells from the
paired primary and recurrent tumors ME/MER and DI/
DIR prior to and following selection for resistance to 10
μg/ml BCNU were treated with 0 – 200 μg/ml S. baicalensis
extract as described in the methods section. Cells were
allowed to grow to form colonies of at least 50 cells. As
seen in Figure 2, cells from all 8 cell lines showed a dose-
dependent response to the S. baicalensis extract.
To demonstrate that the effect of the S. baicalensis extract
on glioma cells was not a result of long-term in vitro culti-
vation of the cells, we tested the extract on cell line 00WA
after 5 serial passages in vitro. This was the minimum
number of passages required to obtain enough cells to
perform the assay. Cells were treated with varying concen-
trations of the S. baicalensis extract as described in the
Methods section, and the percentage of viable cells was
determined by trypan blue exclusion 48 hours later. Fig-
ure 3 shows that the extract caused a dose-dependent
reduction in viability similar to that observed in the ME/
MER and DI/DIR cell line series.
Effects of S. baicalensis on normal glial cells
To assess whether the extract demonstrates toxicity in nor-
mal cells, normal human glial cells (HJ) were plated and
allowed to grow until they were close to confluence. These
cells were then cultured in the presence and absence of
various concentrations of the extract for 48 hours. As
shown in Figure 4, normal glial cells treated with 25–100
μg/ml of S. baicalensis extract for 48 hours displayed no
significant change (p > .05; n = 3) in metabolic activity
assayed using AlamarBlue and compared to the control
(untreated) cells. For comparison, a recurrent glioma cell
line (MER) was also treated with 25-100 μg/ml of the
extract for 48 hours. The glioma cells treated with S. bai-
calensis extract at concentrations of 50 and 100 μg/ml dis-
played a significant reduction (p < .05, n = 3) in metabolic
activity when compared to the metabolic activity of the
control (untreated) cells.
Dose-dependent growth inhibition of a low-passage glioma  cell line by an extract from S. baicalensis Figure 3
Dose-dependent growth inhibition of a low-passage glioma 
cell line by an extract from S. baicalensis. The viability of cell 
line 00WA following treatment with 0–200 μg/ml of S. bai-
calensis extract was tested by trypan blue exclusion at serial 
passage 5. Results are the mean ± SD of 2 replicates and data 
were normalized to the control.
Dose-dependent inhibition of glioma cell proliferation by  Scutellaria baicalensis extract Figure 2
Dose-dependent inhibition of glioma cell proliferation by 
Scutellaria baicalensis extract. Glioma cell lines from primary 
tumors (ME and DI) and recurrent (MER and DIR) tumors, as 
well as BCNU resistant (designated "Drug") glioma cell lines 
were cultured with various concentrations of S. baicalensis 
extract (0–200 μg/ml). After treatment, cells were incubated 
for 14 days to allow for colony growth. Colonies of at least 
50 cells were counted using a 4% Giemsa stain. Results were 
normalized to the control (untreated cells). Data show 
means ± SD of 3 replicates.BMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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Microscopic examination of the cells following treatment
with 100 μg/ml of the extract showed marked differences
in the normal glial cells compared to the tumor cells (Fig-
ure 4B). The MER culture demonstrated an increase in the
number of detached cells floating in the medium. The
floating cells exhibited atypical morphologies such as
DNA condensation, a hallmark of cell death (Figure 4B).
The normal glial (HJ) cells did not show a substantial
increase in floating cells or cells with DNA condensation
or other hallmarks of cell death.
Combination treatment with S. baicalensis and BCNU
To determine if the S. baicalensis extract could potentiate
the effects of conventional chemotherapeutic agents, we
tested the effect of combined treatment using 50 μg/ml of
S. baicalensis extract and 2.5 μg/ml of BCNU on the viabil-
ity of cells from primary and recurrent cells selected for
resistance to 10 μg/ml BCNU (Figure 5A). As expected, 2.5
μg/ml of BCNU alone had no effect on these cells and 50
μg/ml of S. baicalensis extract reduced viability to 15–30%
of control; however, when used in combination survival
was reduced substantially, particularly in the DI and DIR
cell lines. The differences between the individual treat-
ments and the combined treatment were found to be sig-
nificant in all but the ME drug cells by one-way ANOVA
(ME Drug: P = 0.0557 F = 8.785; MER Drug: P = 0.0116 F
= 27.77; DI Drug: P = 0.0005 F = 253.3 and DIR Drug: P =
0.0010 F = 144.1). Fewer than 5% of any of the cells sur-
vived when the BCNU dose was increased to 5 μg/ml,
even though this dose alone caused little, if any, CPE (data
not shown). Microscopic examination of the combined
The effects of Scutellaria baicalensis extract (50 μg/ml) and  BCNU on glioma cell viability in BCNU-resistant and low  passage cell lines Figure 5
The effects of Scutellaria baicalensis extract (50 μg/ml) and 
BCNU on glioma cell viability in BCNU-resistant and low 
passage cell lines. (A) Glioma cell lines from primary and 
recurrent tumors (ME/MER; DI/DIR) selected for resistance 
to 10 μg/ml BCNU (designated "Drug") were treated with 
either 50 μg/ml of S. baicalensis extract alone (Scut.), 2.5 μg/
ml of BCNU alone, or a combination of the S. baicalensis 
extract and BCNU (Scut. + BCNU). (B) Low passage cells 
from tumor 00WA were treated with either 50 μg/ml of S. 
baicalensis extract alone (Scut.), 5 μg/ml of BCNU alone, or a 
combination of the S. baicalensis extract and BCNU (Scut. + 
BCNU). The percentage of viable cells following 3 consecu-
tive days of treatment was assessed using a trypan blue 
exclusion assay. Results are normalized to the control 
(untreated) cells and data is the mean ± SD for 2 replicates.
The cytotoxic effects of Scutellaria baicalensis extract on nor- mal glial cells and glioma cells Figure 4
The cytotoxic effects of Scutellaria baicalensis extract on nor-
mal glial cells and glioma cells. Wells were essentially conflu-
ent at the beginning of the experiment. (A) Metabolic activity 
of normal glial cells (HJ) and cells from a recurrent tumor 
(MER) were measured using the AlamarBlue™ metabolic 
assay. Glioma cells were cultured with 100 μg/ml of the S. 
baicalensis extract for approximately 48 hours. Results were 
presented as a percentage of the control (untreated). Data 
show means ± SD of 3 replicates. (B) Photomicrographs of 
cells 48 hours following treatment with 100 μg/ml of S. bai-
calensis extract.BMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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effects of BCNU and the S. baicalensis extract again indi-
cated an increase in the number of detached (floating)
cells with atypical morphologies when compared to cells
treated with either BCNU or the extract alone (Figure 6).
The effect of combined treatment on low passage, BCNU
naive 00WA cells showed a similar significant potentia-
tion of the drug effect, although the overall effect was less
than that observed with the ME and DI cell series (Figure
5B). BCNU or S. baicalensis extract alone reduced viability
to 75%; however, combination treatment resulted in a
reduction of viability to 30% of the control, mock-treated
cells (p = 0.0141 F = 24.20 by one-way ANOVA).
Discussion
Treatment of malignant brain tumors typically includes
surgery, radiation and chemotherapy; however, this
tumor typically recurs following therapy and the recurrent
tumor is often refractory to additional therapy. The iden-
tification of a novel therapy that is effective against recur-
rent tumor could substantially impact the morbidity and
median survival of patients with this disease. The purpose
of this study was to investigate the effects of plant second-
ary metabolites from Scutellaria baicalensis on cells from
primary and recurrent gliomas prior to, and following,
selection for therapy resistance.
There are many reports of the medicinal utility of the Chi-
nese herb S. baicalensis for the treatment of a host of dis-
eases. Although there have been numerous studies on the
effects of S. baicalensis extracts and isolated flavonoids on
cancer cells, few have studied their effects on glioma cells.
Further, there are no studies examining the effect of
extracts of this herb on cells from tumors that have
recurred following standard therapies. We, therefore,
tested an ethanol extract from S. baicalensis for its ability
to inhibit the growth of cells from primary gliomas, cells
from recurrent gliomas from the same patient and cells
selected for resistance to BCNU therapy in vitro. We also
tested cells cultured from primary gliomas after only 5
serial passages in vitro. Our work demonstrated that the S.
baicalensis extract caused a dose-dependent inhibition of
growth of all of these cell lines, irrespective of whether
they were from a primary or recurrent tumor. Reduced
metabolic activity due to the S. baicalensis extract was
demonstrated using AlamarBlue™, and cytotoxicity was
demonstrated by colony forming assays as well as by
trypan blue exclusion and microscopic examination. A
dose of 50 μg/ml of the extract typically reduced the pop-
ulation of glioma cells by at least 50% of the control
(untreated) population; however, the same dose of extract
had little, if any, effect on HJ cells, the cultured normal
glia. In fact, 25 – 100 μg/ml of S. baicalensis extract did not
induce the same inhibitory effects in HJ cells that were
observed in all of the glioma cells tested. The normal glial
cells also failed to undergo the typical morphological
changes seen following treatment of the glioma cells. This
suggests that the S. baicalensis extract may not affect nor-
mal cells to the extent that it affects tumor cells, thus war-
ranting in vivo studies.
The effect of the S. baicalensis extract on cells from recur-
rent tumor is of particular interest. Recurrent tumor gen-
erally arises from cells in the primary tumor that survived
treatment with radiation and chemotherapy; thus, recur-
rent tumor is often refractile to further therapies. Our data
demonstrates that not only are the cells from recurrent
tumor sensitive to the effects of the S. baicalensis extract,
but cells from primary and recurrent tumor selected for
resistance to 10 μg/ml BCNU are sensitive to lower doses
when given in combination with S. baicalensis extract. This
suggests that this extract may have its greatest utility when
used in combination with currently available therapies.
This work is similar to previous studies showing that S.
baicalensis extracts may reduce tumor growth and prolifer-
ation when applied to chemotherapy and radiation resist-
ant tumors in various forms of cancer [18,43-45]. One
postulated mechanism for this is the inhibition of extra-
cellular signal-regulated kinase (ERK). Pathways involv-
ing ERK are activated in most GBMs [46], and inhibition
of ERK has been shown to inhibit growth of GBMs and
medulloblastomas alone and in combination with temo-
zolomide [47,48].
Photomicrographs of ME Drug cells (selected for resistance  to 10 μg/ml BCNU) treated with either (B) 5 μg/ml BCNU,  (C) 50 μg/ml of S. baicalensis extract, (D) or a combination of  S. baicalensis extract and BCNU Figure 6
Photomicrographs of ME Drug cells (selected for resistance 
to 10 μg/ml BCNU) treated with either (B) 5 μg/ml BCNU, 
(C) 50 μg/ml of S. baicalensis extract, (D) or a combination of 
S. baicalensis extract and BCNU. Glioma cells were treated 
for 3 consecutive days and then compared to the (A) control 
(untreated) cells.BMC Complementary and Alternative Medicine 2006, 6:27 http://www.biomedcentral.com/1472-6882/6/27
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The effects of extracts and isolated flavonoids are not all
antiproliferative. Choi et al [49] found that an aqueous
extract from S. baicalensis reduced the apoptotic death
induced in neuronal HT-22 cells exposed to H2O2 by
increased Bcl-2 and reducing Bax levels. In addition, bai-
calein, a major component of the S. baicalensis extract, can
exert either pro- or anti-apoptotic activity depending on
the cell type. For example, in addition to its antiprolifera-
tive effects, baicalein has been shown to prevent the loss
of viability and apoptosis induced in the human glioma
cell line A172 by cisplatin [50]. Regardless of this, our
data has demonstrated a potential role for the use of S.
baicalensis  as an adjuvant therapy in the treatment of
human malignant brain tumors, particularly recurrent
tumors.
Conclusion
In summary, the results of this study support the efficacy
of S. baicalensis as an anticancer agent for glioblastomas
multiforme and a potential adjuvant treatment to current
chemotherapeutic agents used in the treatment of both
primary and recurrent GBMs. Further studies of the effects
of individual flavonoids alone and in combination with
each other and with currently used therapies are in
progress.
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